205 related articles for article (PubMed ID: 24246210)
21. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
[TBL] [Abstract][Full Text] [Related]
22. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
[TBL] [Abstract][Full Text] [Related]
23. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
24. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).
Otsuka A; Kageyama S; Suzuki T; Matsumoto R; Nagae H; Kitagawa M; Furuse H; Ozono S
Int J Urol; 2016 Dec; 23(12):1016-1023. PubMed ID: 27686226
[TBL] [Abstract][Full Text] [Related]
25. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
26. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
[TBL] [Abstract][Full Text] [Related]
27. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
Chapple CR; Abrams P; Andersson KE; Radziszewski P; Masuda T; Small M; Kuwayama T; Deacon S
J Urol; 2014 Jan; 191(1):253-60. PubMed ID: 24018240
[TBL] [Abstract][Full Text] [Related]
28. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
Kelleher CJ; Tubaro A; Wang JT; Kopp Z
BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
Homma Y; Yamaguchi O;
Int J Urol; 2009 May; 16(5):499-506. PubMed ID: 19389083
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies.
Herschorn S; Jones JS; Oelke M; MacDiarmid S; Wang JT; Guan Z
Urology; 2010 May; 75(5):1149-55. PubMed ID: 19914702
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
Kaplan SA; Cardozo L; Herschorn S; Grenabo L; Carlsson M; Arumi D; Crook TJ; Whelan L; Scholfield D; Ntanios F;
Int J Clin Pract; 2014 Sep; 68(9):1065-73. PubMed ID: 24898471
[TBL] [Abstract][Full Text] [Related]
32. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
[TBL] [Abstract][Full Text] [Related]
34. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
36. A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan.
Chuang YC; Lin CC; Chow PM; Lien CS; Tsui KH; Chou CL; Lee HY; Meng E; Kuo HC
Low Urin Tract Symptoms; 2021 Jan; 13(1):108-117. PubMed ID: 32844599
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
[TBL] [Abstract][Full Text] [Related]
40. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
